Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Вирусные гепатиты у детей
Вирусные гепатиты у детей
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Рейзис А.Р., Матанина Н.В. Урсодеоксихолевая кислота и ее применение при вирусных гепатитах у взрослых и детей. Клинич. персп. гастроэнтерол., гепатол. М., 2005; 6: 11–5 .
2. Рейзис А.Р., Никитина Т.С., Дрондина А.К. и др. Поддерживающая терапия поражений печени и желчевыводящих путей у детей и подростков с вирусными гепатитами, протекающими на фоне различной соматической патологии. Рос. журн.
гастроэнтерол., гепатол., колопроктол. М., 2004; 1 (14): 83.
3. Barlow CF, Priebe CJ, Mulliken JB et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr 1988; 132: 527–30.
4. Bhimma R, Coovadia HM, Kramvis A et al. Treatment of hepatitis B virus-associated nephropathy in black children. Pediatr Nephrol 2002; 17: 393–9 .
5. Carithers RI, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997; 26 (Suppl.): 83–8S.
6. Dikici B, Bosnak M, Bosnak V et al. Comparison of treatments of chronic hepatitis B in children with lamivudine and alphainterferon combination and alpha-interferon alone. Pediatrics Int 2002; 44: 517–21.
7. Feld J, Lee J-Y, Locarnini S. New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. Hepatology 2003; 38: 545–53.
8. Jacobson KB, Murray K, Zellos A, Schwarz KB. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002; 343: 52–8 .
9. Jonas MM, Kelley DA, Mizerski J et al. Clinical trial of lamivudine in children with chronic hepati tis B. N Engl J Med 2002; 346: 1706–13.
10. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B 2000, summary of a workshop. Gastroenterol 2001; 120: 1828–53.
11. Schwarz KB. Pediatric issues in new therapies for hepatitis B and C. Curr Gastroenterol Rep 2003; 5: 233–9 .
12. Schwarz KB, Mohan P, Narkewicz M et al. The safety, efficacy and pharmacokinetics of peginterferon Alfa-2a (40KD) in children with chronic hepatitis C. DDW 2003; 124 (Suppl. 1): A700.
13. Sshwarz KB. Viral hepatitis in children. Advanced Therapy in gastroenterology and liver disease. Bayless Theodore M, Diehl Anna Mae (eds.), 2005; 108: 625–8 .
14. Shapira R, Mor E, Bar-Nathan N et al. Efficacy of lamivudine for the treatment of hepatitis B virus infection after live transplantation in children. Transplantation 2001; 72: 333–6 .
15. Sokal EM, Conjeevaram HS, Roberts EA et al. Interferon alfa therapy for chronic hepatitis B in children: a multicenter controlled trial. Hepatology 1996; 23: 700–7 .
16. Torre D, Tambini R. Interferon-alpha treatment of chronic hepatitis B in childhood: a meta-analysis. Clin Infect Dis 1996; 23: 131–7 .
17. Wirth S, Lang T, Gehring S, Gerner P. Recombinant alfainterferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology 2002; 36: 585–6 .
2. Рейзис А.Р., Никитина Т.С., Дрондина А.К. и др. Поддерживающая терапия поражений печени и желчевыводящих путей у детей и подростков с вирусными гепатитами, протекающими на фоне различной соматической патологии. Рос. журн.
гастроэнтерол., гепатол., колопроктол. М., 2004; 1 (14): 83.
3. Barlow CF, Priebe CJ, Mulliken JB et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr 1988; 132: 527–30.
4. Bhimma R, Coovadia HM, Kramvis A et al. Treatment of hepatitis B virus-associated nephropathy in black children. Pediatr Nephrol 2002; 17: 393–9 .
5. Carithers RI, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997; 26 (Suppl.): 83–8S.
6. Dikici B, Bosnak M, Bosnak V et al. Comparison of treatments of chronic hepatitis B in children with lamivudine and alphainterferon combination and alpha-interferon alone. Pediatrics Int 2002; 44: 517–21.
7. Feld J, Lee J-Y, Locarnini S. New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. Hepatology 2003; 38: 545–53.
8. Jacobson KB, Murray K, Zellos A, Schwarz KB. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002; 343: 52–8 .
9. Jonas MM, Kelley DA, Mizerski J et al. Clinical trial of lamivudine in children with chronic hepati tis B. N Engl J Med 2002; 346: 1706–13.
10. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B 2000, summary of a workshop. Gastroenterol 2001; 120: 1828–53.
11. Schwarz KB. Pediatric issues in new therapies for hepatitis B and C. Curr Gastroenterol Rep 2003; 5: 233–9 .
12. Schwarz KB, Mohan P, Narkewicz M et al. The safety, efficacy and pharmacokinetics of peginterferon Alfa-2a (40KD) in children with chronic hepatitis C. DDW 2003; 124 (Suppl. 1): A700.
13. Sshwarz KB. Viral hepatitis in children. Advanced Therapy in gastroenterology and liver disease. Bayless Theodore M, Diehl Anna Mae (eds.), 2005; 108: 625–8 .
14. Shapira R, Mor E, Bar-Nathan N et al. Efficacy of lamivudine for the treatment of hepatitis B virus infection after live transplantation in children. Transplantation 2001; 72: 333–6 .
15. Sokal EM, Conjeevaram HS, Roberts EA et al. Interferon alfa therapy for chronic hepatitis B in children: a multicenter controlled trial. Hepatology 1996; 23: 700–7 .
16. Torre D, Tambini R. Interferon-alpha treatment of chronic hepatitis B in childhood: a meta-analysis. Clin Infect Dis 1996; 23: 131–7 .
17. Wirth S, Lang T, Gehring S, Gerner P. Recombinant alfainterferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology 2002; 36: 585–6 .
Авторы
Т.Е.Полунина, И.В.Маев
Кафедра пропедевтики внутренних болезней и гастроэнтерологии (зав. – проф. И.В.Маев) МГМСУ
Кафедра пропедевтики внутренних болезней и гастроэнтерологии (зав. – проф. И.В.Маев) МГМСУ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.